Differential effects of troglitazone and D-chiroinositol on glucosamine- induced insulin resistance in vivo in rats

Metabolism: Clinical and Experimental

Volumn 48, Issue 11, 1999, Pages 1418-1423

  Yoshino, Koji ^a   Takeda, Noriyuki ^a   Sugimoto, Miyuki ^a   Nakashima, Kazuya ^a   Okumura, Shoji ^a   Hattori, Junko ^a   Sasaki, Akihiko ^a   Kawachi, Shinichi ^a   Takami, Kazuhisa ^a   Takami, Rieko ^a   Yasuda, Keigo ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSAMINE; INOSITOL DERIVATIVE; TROGLITAZONE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; INSULIN METABOLISM; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 13044256395     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90153-1     Document Type: Article

References (57)

1. DeFronzo RA: The triumvirate: β-Cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667-687, 1988
2. Rossetti L, Giaccari A, DeFronzo RA: Glucose toxicity. Diabetes Care 13:610-630, 1990
3. Yki-Järvinen H: Glucose toxicity. Endocr Rev 13:415-431, 1992
4. Marshall S, Bacote V, Traxinger RR: Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 266:4706-4712, 1991
5. Rossetti L, Hawkins M, Chen W, et al: In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats. J Clin Invest 96:132-140, 1995
6. Giaccari A, Morviducci L, Zorretta D, et al: In vivo effects of glucosamine on insulin secretion and insulin sensitivity in the rat: Possible relevance to the maladaptive responses to chronic hyperglycaemia. Diabetologia 38:518-524, 1995
7. Baron AD, Zhu JS, Zhu JH, et al: Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity. J Clin Invest 96:2792-2801, 1995
8. Virkamäki A, Daniels MC, Hamalainem S, et al: Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance in multiple insulin sensitive tissues. Endocrinology 138:2501-2507, 1997
9. Hawkins M, Barzilai N, Chen W, et al: Increased hexosamine availability similarly impairs the action of insulin and IGF-1 on glucose disposal. Diabetes 45:1734-1743, 1996
10. Robinson KA, Sens DA, Buse MG: Pre-exposure to glucosamine induces insulin resistance of glucose transport and glycogen synthesis in isolated rat skeletal muscles. Study of mechanisms in muscle and in rat-1 fibroblasts overexpressing the human insulin receptor. Diabetes 42:1333-1346, 1993
11. Furnsinn C, Sanderson AL, Radda GK, et al: Effects of glucosamine on insulin-stimulated glucose metabolism in rat soleus muscle. Int J Biochem Cell Biol 27:805-814, 1995
12. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 40:1661-1669, 1996
13. Huang L, Larner J: Inositolphosphoglycan mediators of insulin action. The special role of chiroinositol in insulin resistance. Adv Prot Phosphatases 7:373-392, 1993
14. Kennington AS, Hill CR, Craig J, et al: Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. N Engl J Med 323:373-378, 1990
15. Ortmeyer HK, Bodkin NL, Lilley K, et al: Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys. Endocrinology 132:640-645, 1993
16. Suzuki S, Kawasaki H, Satoh Y, et al: Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. Diabetes Care 17:1465-1468, 1994
17. Ortmeyer HK, Huang LC, Zhang L, et al: Chiroinositol deficiency and insulin resistance. II. Acute effects of D-chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistant rhesus monkeys. Endocrinology 132:646-651, 1993
18. Huang LC, Fonteles MC, Houston DB, et al: Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo. Endocrinology 132:652-657, 1993
19. Fonteles MC, Huang LC, Larner J: Infusion of pH 2.0 D-chiroinositol glycan insulin putative mediator normalizes plasma glucose in streptozotocin diabetic rats at a dose equivalent to insulin without inducing hypoglycemia. Diabetologia 39:731-734, 1996
20. Nestler JE, Jakubowicz DJ, Reamer P, et al: Effects of D-chiro-inositol (INS-1) on insulin, glucose and spontaneous ovulation in obese women with polycystic ovary syndrome (PCOS). Diabetes 47:A91, 1998 (suppl 1, abstr)
21. Kessler C, Allan G, Larner J: D-Chiro-inositol improves insulin and glucose profiles in human subjects with impaired glucose tolerance. Diabetes 47:A358,1998 (suppl 1, abstr)
22. Fujiwara T, Yoshioka S, Yoshioka T, et al: Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
23. Yoshioka S, Nishino H, Shiraki T, et al: Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42:75-80, 1993
24. Hirai T, Suzuki S, Toyota T: Improvement of insulin resistance by D-chiro-inositol administration. Diabetes Front 4:637-638, 1993
25. Ortmeyer HK, Lamer J, Hansen BC, et al: Effects of D-chiroinositol added to a meal on plasma glucose and insulin in hyperinsulinemic rhesus monkeys. Obes Res 3:605S-608S, 1995 (suppl 4)
26. Okumura S, Takeda N, Takami K, et al: Effects of troglitazone on dexamethasone-induced insulin resistance in rats. Metabolism 47:351-354, 1998
27. Borel MJ, Beard JL, Farrell PA: Hepatic glucose production and insulin sensitivity and responsiveness in iron-deficient anemic rats. Am J Physiol 264:E380-E390, 1993
28. Kraegen EW, James DE, Jenkins AB, et al: Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. Am J Physiol 248:E353-E362, 1985
29. Terrettaz J, Jeanrenaud B: In vivo hepatic and peripheral insulin resistance in genetically obese (fa/fa) rats. Endocrinology 112:1346-1351, 1983
30. Barzilai N, Hawkins M, Angelov I, et al: Glucosamine-induced inhibition of liver glucokinase impairs the ability of hyperglycemia to suppress endogenous glucose production. Diabetes 45:1329-1335, 1996
31. Nerlich AG, Sauer U, Kolm-Litty V, et al: Expression of glutamine:fructose-6-phosphate amidotransferase in human tissues. Diabetes 47:170-178, 1988
32. Yki-Järvinen H, Vogt C, Iozzo P, et al: UDP-N-acetylglucosamine transferase and glutamine:fructose-6-phosphate amidotransferase activities in insulin-sensitive tissues. Diabetologia 40:76-81, 1997
33. Robinson KA, Weinstein ML, Lindenmayer GE, et al: Effect of diabetes and hyperglycemia on the hexosamine synthesis pathway in rat muscle and liver. Diabetes 44:1438-1446, 1995
34. Buse MG, Robinson KA, Gettys TW, et al: Increased activity of hexosamine synthesis pathway in muscles of insulin-resistant ob/ob mice. Am J Physiol 272;E1080-E1088, 1997
35. Fujiwara T, Okuno A, Yoshioka S, et al: Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 44:486-490, 1995
36. Sugimoto M, Takeda N, Nakashima K, et al: Effect of troglitazone on hepatic and peripheral insulin resistance induced by growth hormone excess in rats. Metabolism 47:783-787, 1998
37. Spencer CM, Markham A: Troglitazone. Drugs 54:89-101, 1997
38. Miles PDG, Higo K, Romero OM, et al: Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance. Diabetes 47:395-400, 1998
39. Yasunari K, Kohno M, Kano H, et al: Mechanism of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells. Circ Res 81:953-962, 1997
40. Berger J, Biswas G, Hayes N, et al: An antidiabetic thiazolidine-dione potentiates insulin stimulation of glycogen synthase in rat adipose tissue. Endocrinology 137:1984-1990, 1996
41. Kellerer M, Kroder G, Tippmer S, et al: Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes 43:447-453, 1994
42. Ciaraldi TP, Gilmore A, Olefsky JM, et al: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39:1056-1062, 1990
43. Murano K, Inoue Y, Emoto M, et al: CS-045, a new oral antidiabetic agent, stimulates fructose-2,6-bisphosphate production in rat hepatocytes. Eur J Pharmacol 254:257-262, 1994
44. O'Rourke CM, Davis JA, Saltiel AR, et al: Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus. Metabolism 46:192-198, 1997
45. Matsushima M, Shi ZQ, Wan C, et al: The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs. Diabetes 46:224-231, 1997
46. Tominaga M, Igarashi M, Daimon M, et al: Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocr J 40:343-349, 1993
47. McClain DA, Crook ED: Hexosamines and insulin resistance. Diabetes 45:1003-1009, 1996
48. Hawkins M, Brzilai N, Liu R, et al: Role of the glucosamine pathway in fat-induced insulin resistance. J Clin Invest 99:2173-2181, 1997
49. Hawkins M, Angelov I, Liu R, et al: The tissue concentration of UDP-N-acetylglucosamine modulates the stimulatory effect of insulin on skeletal muscle glucose uptake. J Biol Chem 272:4889-4895, 1997
50. Doering TL, Masterson WJ, Englund PT, et al: Biosynthesis of the glycosyl phosphatidylinositol membrane anchor of the trypanosome variant surface glycoprotein. J Biol Chem 264:11168-11173, 1989
51. Varela-Nieto I, Leon Y, Caro HN: Cell signalling by inositol phosphoglycans from different species. Comp Biochem Physiol 115B: 223-241, 1996
52. Müller G, Dearey EA, Korndörfer A, et al: Stimulation of a glycosyl-phosphatidylinositol-specific phospholipase by insulin and the sulfonylurea, glimepiride, in rat adipocytes depends on increased glucose transport. J Cell Biol 126:1267-1276, 1994
53. Yki-Järvinen H, Daniels MC, Virkamäki A, et al: Increased glutamine:fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. Diabetes 45:302-307, 1996
54. Macaulay SL, Larkins RG: Isolation of insulin-sensitive phosphatidylinositol-glycan from rat adipocytes. Biochem J 271:427-435, 1990
55. Sänchez-Arias JA, Sänchez-Gutierrez JC, Guadano A, et al: Impairment of glycosyl-phosphatidylinositol-dependent insulin signaling system in isolated rat hepatocytes by streptozotocin-induced diabetes. Endocrinology 131:1727-1733, 1992
56. Sänchez-Gutierrez JC, Sänchez-Arias JA, Valle JC, et al: Insulin resistance in genetically obese (fa/fa) rats: Changes in the glycosyl-phosphatidylinositol signaling system in isolated hepatocytes. Endocrinology 134:1485-1492, 1994
57. Shashkin PN, Shashkina EF, Ferqvist-Forves E, et al: Insulin mediators in man: Effects of glucose ingestion and insulin resistance. Diabetologia 40:557-563, 1997